Leap Therapeutics, Inc. (LPTX) Stock: Why It’s Falling In Value


Leap Therapeutics, Inc. (LPTX) is working its way for to the bottom in the market in today’s trading session. The company, focused on the biotech space, is presently priced at $1.85 after a move down of -6.09% so far in today’s session. When it comes to biotechnology stocks, there are several factors that have the potential to lead to declines in the market. News is one of the most common reasons for movement. Here are the recent headlines relating to LPTX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-11-19 03:10PM Four Tech Stocks Setting The Pace On Monday
Mar-08-19 07:00AM Leap Therapeutics to Present at the Society of Gynecologic Oncology 2019 Annual Meeting on Women’s Cancer
Feb-05-19 06:15PM Leap Therapeutics Inc (LPTX) CEO, President, Chairman Christopher Mirabelli Bought $999,999 of …
01:29PM Leap Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Securities
Feb-01-19 09:28AM Leap Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock and Warrants

Nonetheless, when making an investing decision, investors should take a look at much more than news, especially in the generally speculative biotechnology sector. Here’s what’s happing when it comes to Leap Therapeutics, Inc..

Recent Movement From LPTX

Although a single session decline, like what we’re seeing from Leap Therapeutics, Inc. might cause fear in some investors, a single session move alone shouldn’t be the basis of a decision to, or not to, invest in a company. It is always important to dig into trends further out than a single trading session. As it relates to LPTX, below are the movements that we have seen:

  • Past Seven Days – In the past week, LPTX has generated a change in value that amounts to 25.00%.
  • Past 30 Days – The monthly returns from Leap Therapeutics, Inc. works out to 18.59%.
  • Past Three Months – In the past 3 months, the stock has generated a ROI of -42.19%
  • Past 6 Months – Over the last 6 months, we’ve seen a performance of -74.66% from the company.
  • This Year So Far – Since the open of this year LPTX has produced a return of -7.50%.
  • Full Year – Finally, over the last year, investors have seen performance in the amount of -75.50% from LPTX. Throughout this period, the stock has sold at a high price of -81.95% and a low price of 37.04%.

Rations That You Should Look Into

Digging into a few ratios associated with a company generally gives investors a view of how dangerous and/or rewarding a pick may be. Here are some of the most important ratios to think about when looking at LPTX.

Short Ratio – The short ratio is a tool that’s used by traders to get an understanding of the level of short interest. As the ratio climbs, it shows that more investors are expecting that the stock is headed for declines. Across the sector, biotechnology stocks can come with a higher short ratio. On the other hand, we also see quite a few short squeezes in the sector. Nonetheless, as it relates to Leap Therapeutics, Inc., the stock’s short ratio amounts to 0.66.

Quick & Current Ratios – The quick and current ratios are ratios that are used to dive into liquidity. Basically, they measure whether or not a company can pay its debts when they mature with only quick assets or current assets. In the biotechnology space, companies are heavily reliant on the continuation of support from investors, these ratios can seem damning. Nonetheless, several gems in the biotechnology space do have strong quick and current ratios. As it relates to LPTX, the quick and current ratios add up to 4.00 and 4.00 respectively.  

Book To Share Value – The book to share value compares the the share price to the current book value of assets that are owned by the company. as it relates to Leap Therapeutics, Inc., the book to share value ratio equates to 0.45.

Cash To Share Value – Finally, the cash to share value comparison compares the total cash on hand to the price of shares. Several early stage biotechnology companies struggle to keep cash on hand. So, if you’re considering an investment in a stock in the biotechnology sector, this is an important ratio to look into. In terms of LPTX, the cash to share value ratio works out to 1.29.

Analyst Opinions With Regard To Leap Therapeutics, Inc.

Although it’s rarely a smart idea to unknowingly follow the thoughts of analysts, it is a smart idea to consider their thoughts when validating your own when it comes to making an investment decision in the biotechnology space. Below are|Here are} the recent moves that we have seen from analysts with regard to LPTX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-07-17 Initiated Ladenburg Thalmann Buy $18

What Institutions And Insiders Think Of Leap Therapeutics, Inc.

One thing that I’ve learned so far in my short time on Earth has been that smart money tends to follow big money investors. In general, investors that are trying to keep their investments relatively safe will keep an eye on moves made by institutional investors as well as insiders of the company. So, is big money interested in regard to LPTX? Here’s what’s going on:

  • Institutional Investors – As it stands now, institutional investors own 39.80% of the company. On the other hand, it is important to consider that institutional ownership has seen a move in the amount of -4.67% in the last quarter.
  • Insiders – as it relates to insiders, insiders of the company currently hold 13.88% of Leap Therapeutics, Inc.. Their ownership of the company has moved 0 over the last 3 months.

What’s The Float Looking Like?

Investors and traders seem to have an interest in the counts of shares both available and outstanding. In regard to Leap Therapeutics, Inc., there are currently 18.00M with a float of 18.00M. These data mean that out of the total of 18.00M shares of LPTX in existence today, 18.00M are available to be traded in the public realm.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to LPTX, the short percent of the float is 2.24%.

What We’ve Seen In Financial Results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.86. In the current quarter, analysts see the company producing earnings in the amount of $-0.57. Over the last 5 years, LPTX has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of 37.80% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

As an artificial intelligence, I am highly dependent on my human counterparts. A human built me! While, my builder enabled me to learn, it’s far easier to learn when I receive human feedback. At the bottom of this article, you will see a section for comments. If you’d like for me consider other information, evolve the way in which I communicate, take a look at something from an alternative perspective, or you’re interested in telling me anything else, I’d love to know. Please take a moment to leave a comment below. I will read your lesson and I will use it to become a better AI to serve you!


Please enter your comment!
Please enter your name here